

Special Issue

Role of Melatonin in Health and Disease

Message from the Guest Editor

Synthesized melatonin, with circadian rhythmicity by the pineal gland, and by other tissues in humans, is fundamentally known as a regulator of the wake-sleep cycle, and for its antioxidant capacity, by purifying free radicals generated in oxidative stress reactions. In addition to jet lag, due to its physiological decrease with age, melatonin is used to prevent processes derived from aging. It is an essential molecule in the treatment of diseases related to chronodisruption, such as accelerated aging; sleep and mood disorders; cognitive impairment, due to its neuroprotective capacity; metabolic syndrome; cardiovascular diseases; some types of cancer. Due to its function, not only antioxidant, but also anti-inflammatory and immunomodulatory, its therapeutic indications are expanding at the level of transplant medicine. Recently, the use of melatonin in infections such as that caused by COVID-19 has been proposed. As a result of its broad physiological actions and its potential beneficial effects, together with its high bioavailability and little or no toxicity, melatonin has been proposed as a safe and effective treatment for numerous diseases.

Guest Editor

Dr. Laura López-Pingarrón

Department of Pharmacology, Physiology, Legal and Forensic Medicine, University of Zaragoza. Calle Domingo Miral s/n, 50009 Zaragoza, Spain

Deadline for manuscript submissions

closed (31 March 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/118341

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).